Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01195662 · ClinicalTrials.gov registry record · Phase 3
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,245
- Enrollment target
NCT01195662: Completed Phase 3 study, sponsored by AstraZeneca.
NCT01195662 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 2,245 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (191% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01195662, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,245 participants
- Enrollment target
Study Summary
The purpose of this study is to learn if BMS-512148 (Dapagliflozin), after 12 weeks, can improve (decrease) blood pressure in patients with type 2 diabetes with uncontrolled hypertension who are on an Angiotensin-converting enzyme inhibitor (ACEI) or an Angiotensin Receptor Blocker (ARB).The safety of this treatment will also be studied
Primary Outcome
Systolic blood pressure (SBP) was measured in millimeters of mercury (mmHg) on Day -1, Day 1, Weeks 2, 4, 8, and 12 of the Double Blind Period. Blood pressure (BP) values were obtained after the participant was seated for quietly for 10 minutes; a mean of 3 replicate measurements was taken at least 1 minute apart. However, if the 3 consecutive seated BP readings were not within 8 mm Hg of each other, an additional 2 BP readings were obtained (total = 5) and incorporated into the calculated mean.
Interventions
- DRUG Dapagliflozin
- DRUG Placebo matching Dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,245 participants |
| Start Date | 2010-10 |
| Est. Completion | 2013-02 |
| Phase | Phase 3 |
What the finished NCT01195662 record still lists
NCT01195662 is an interventional study that assigns participants to a tested intervention. Its 2,245 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (191% higher).
The record links to 0 conditions, and to 2 interventions - of which Dapagliflozin is the first listed.
NCT01195662 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01195662 about?
NCT01195662 is a clinical study titled "A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication". The purpose of this study is to learn if BMS-512148 (Dapagliflozin), after 12 weeks, can improve (decrease) blood pressure in patients with type 2 diabetes with uncontrolled hypertension who are on an Angiotensin-converting enzyme inhibitor (ACEI) or an Angiotensin Receptor Blocker (ARB).The safety ...
What is the current status of trial NCT01195662?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,245 participants. The study started on 2010-10. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01195662?
The interventions under investigation include: Dapagliflozin (DRUG), Placebo matching Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT01195662?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01195662's enrollment target sits among peer trials
2,245 95th of 2000 higher than 1,906 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04889872 · 2,250 participants · NA
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
- NCT06805513 · 2,250 participants · Phase 3
Actual Use Trial of Tadalafil 5 mg
- NCT06939803 · 2,236 participants · NA
AI-driven Clinical Decision Support to Reduce Hospital-Acquired Venous Thromboembolism: Study Protocol for the VTE-AI Randomized Trial.
- NCT06831929 · 2,232 participants · NA
HPV Ends Here: Increasing Uptake of the HPV Vaccine
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia